Prognostic value of PSA Kinetic Ratio in high-volume mCSPC patients treated with abiraterone or enzalutamide: a single-center retrospective study.

BMC Cancer · 2026 · PMC13245084 · PMID 41987096

Europe PMC DOI

hedged sentence

0.0640

closest p · 1.3× alpha

0.0640

boldest claim

The sentences

did not reach statistical significancep = 0.064so close (0.05 < p ≤ 0.1)

13.8 months); however, this difference did not reach statistical significance (log-rank p = 0.064, Fig. 1 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.